NCT05397041View on ClinicalTrials.gov

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Healthy
Interventions
DRUG

BMB-101

Participants will receive one of several different oral doses of BMB-101 once or twice daily

DRUG

Placebo

Matched Placebo

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
lead

Bright Minds Biosciences Pty Ltd

INDUSTRY

NCT05397041 - A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers | Biotech Hunter | Biotech Hunter